GeneDx (WGS) CEO Stueland sells 10,501 shares in tax sell-to-cover
Rhea-AI Filing Summary
GeneDx Holdings Corp. CEO Katherine Stueland reported routine equity compensation activity and related tax sales. On June 16, 2026, she exercised restricted stock units, acquiring 18,750 shares of Class A Common Stock upon RSU vesting.
On the same date she sold a total of 10,501 shares of Class A Common Stock in open-market transactions at weighted average prices around $59.75–$61.50 per share to cover tax withholding obligations from the RSU vesting, described as a non-discretionary “sell to cover” transaction. After these transactions, she beneficially owned 104,372 shares of Class A Common Stock, plus RSUs for up to 305,525 shares and options for up to 107,610 shares that vest under their terms.
Positive
- None.
Negative
- None.
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
5 txns
Insider
Stueland Katherine
Role
CHIEF EXECUTIVE OFFICER
Sold
10,501 shs ($638K)
Approx. gross sale proceeds
$638K
Approx. exercise cost
$0.00
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 18,750 | $0.00 | $0.00 |
| Exercise | Class A Common Stock | 18,750 | $0.00 | $0.00 |
| Sale | Class A Common Stock | 2,140 | $59.7543 | $128K |
| Sale | Class A Common Stock | 5,932 | $60.8291 | $361K |
| Sale | Class A Common Stock | 2,429 | $61.5035 | $149K |
Holdings After Transaction:
Restricted Stock Unit — 56,250 shares (Direct);
Class A Common Stock — 104,372 shares (Direct)
Footnotes (7)
- F1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
- F2. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.26 to $60.24 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 4 and 5 of this Form 4.
- F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.40 to $61.35 per share, inclusive.
- F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.44 to $61.69 per share, inclusive.
- F6. Following the reported sale undertaken to satisfy tax withholding liabilities, in addition to the 104,372 shares of Class A Common Stock beneficially owned by the Reporting Person, the Reporting Person held RSUs representing contingent rights to receive up to an aggregate 305,525 shares of the Issuer's Class A Common Stock and options to purchase up to an aggregate 107,610 shares of Class A Common Stock, which RSUs and options vest according to their respective terms.
- F7. 6.25% of the total award vested or vests quarterly, with the first tranche vested on June 16, 2023, subject to the Reporting Person's continued service to the Issuer on each vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.
Key Figures
Shares sold to cover taxes: 10,501 shares
RSU shares acquired: 18,750 shares
Post-transaction common shares: 104,372 shares
+5 more
8 metrics
Shares sold to cover taxes
10,501 shares
Open-market sales on June 16, 2026
RSU shares acquired
18,750 shares
Class A Common Stock from RSU vesting
Post-transaction common shares
104,372 shares
Class A Common Stock beneficially owned after transactions
RSUs outstanding
305,525 shares
Contingent rights to Class A Common Stock after transactions
Options outstanding
107,610 shares
Options to purchase Class A Common Stock after transactions
Sale price range (block 1)
$59.26–$60.24
Weighted average price range cited in footnote
Sale price range (block 2)
$60.40–$61.35
Weighted average price range cited in footnote
Sale price range (block 3)
$61.44–$61.69
Weighted average price range cited in footnote
Key Terms
Restricted Stock Unit, sell to cover, weighted average price, beneficially owned, +1 more
5 terms
Restricted Stock Unit financial
"Each restricted stock unit ("RSU") represents a contingent right to receive 1 share..."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
sell to cover financial
"to be funded by a "sell to cover" transaction and does not represent a discretionary transaction..."
Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.
weighted average price financial
"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions..."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
beneficially owned financial
"in addition to the 104,372 shares of Class A Common Stock beneficially owned by the Reporting Person..."
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
tax withholding obligations financial
"shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs..."
FAQ
What did GeneDx (WGS) CEO Katherine Stueland report in this Form 4?
Katherine Stueland reported RSU vesting and related tax sales. She acquired 18,750 shares from RSUs and sold 10,501 shares of Class A Common Stock in open-market transactions to cover tax withholding obligations from the vesting event.
Was the GeneDx (WGS) CEO’s stock sale a discretionary transaction?
No, the sale is described as non-discretionary. Footnotes state the 10,501 shares were sold solely to cover tax withholding obligations from RSU vesting through a “sell to cover” transaction, rather than a discretionary decision to reduce holdings.
What are Katherine Stueland’s GeneDx (WGS) holdings after these transactions?
After the transactions, she beneficially owned 104,372 shares of Class A Common Stock. She also held RSUs for up to 305,525 additional shares and options to purchase up to 107,610 shares, all vesting in the future according to their respective terms.
How do the GeneDx (WGS) CEO’s RSUs vest over time?
A related footnote explains 6.25% of the RSU award vests quarterly. The first tranche vested on June 16, 2023, and continued vesting is conditioned on her ongoing service to GeneDx on each vesting date until all RSUs either vest or are cancelled.
AI-generated analysis. How Rhea-AI works. Not financial advice.
